Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Fineline Cube Jan 13, 2026
Company Medical Device

GE Healthcare’s SIGNA MAGNUS MRI Scanner Receives FDA 510(k) Clearance

Fineline Cube Nov 14, 2024

US medical device and life sciences leader GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals

Cullgen and Pulmatrix Merge to Form Nasdaq-Listed Protein Degradation Company

Fineline Cube Nov 14, 2024

Cullgen Inc., a clinical-stage biopharmaceutical company with operations in China, the US, and Japan, is...

Company Drug

ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer

Fineline Cube Nov 14, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...

Company Drug

Huadong Medicine’s Biosimilar SaiLeXin Receives First National Prescription in China

Fineline Cube Nov 14, 2024

China-based pharmaceutical company Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant milestone with...

Company Deals

Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund

Fineline Cube Nov 14, 2024

Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic...

Company Drug

Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment

Fineline Cube Nov 14, 2024

The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...

Company Drug

Daiichi Sankyo and AstraZeneca File BLA for Datopotamab Deruxtecan in NSCLC

Fineline Cube Nov 14, 2024

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN), partners in the development of innovative...

Company Deals

Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research

Fineline Cube Nov 14, 2024

China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed...

Company Deals

BioNTech Seals Acquisition of China’s Biotheus for Up to $950M

Fineline Cube Nov 14, 2024

China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...

Company Deals

Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China

Fineline Cube Nov 14, 2024

China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical...

Company

Pfizer Considers Sale of Hospital Unit Amid Pressure from Starboard Value

Fineline Cube Nov 14, 2024

Pfizer Inc. (NYSE: PFE) is reportedly considering the sale of its hospital unit, Pfizer Hospital,...

Company

FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo

Fineline Cube Nov 13, 2024

US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing...

Company

AstraZeneca Inc. Reports 21% YOY Revenue Growth in Q3 2024 Financials

Fineline Cube Nov 13, 2024

UK-based pharmaceutical giant AstraZeneca Inc. (AZ, NASDAQ: AZN) has reported its financial performance for the...

Company

BeiGene’s Q3 2024 Results Show 28% YOY Revenue Growth Driven by Brukinsa and Tevimbra

Fineline Cube Nov 13, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a China-based biotech company, has released its...

Company

Bayer AG Posts Modest Q3 Growth with Strong Performance from New Pharmaceuticals

Fineline Cube Nov 13, 2024

Germany-based Bayer AG (ETR: BAYN) has released its Q3 2024 financial results, reporting a 0.6%...

Company Deals

Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881

Fineline Cube Nov 13, 2024

China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has...

Company Deals

Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange

Fineline Cube Nov 13, 2024

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin...

Company Deals

Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research

Fineline Cube Nov 13, 2024

Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the...

Company Medical Device

J&J MedTech Receives FDA IDE for OTTAVA Robotic Surgical System Trials

Fineline Cube Nov 13, 2024

US-based Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received an...

Company

Zai Lab Ltd Reports 46% YOY Revenue Growth in Q3 2024 Driven by Vygart, Zejula, and Nuzyra

Fineline Cube Nov 13, 2024

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its Q3 2024 financial...

Posts pagination

1 … 210 211 212 … 609

Recent updates

  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
  • Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk
  • ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform
  • Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Company Medical Device

Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk

Company Drug

ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.